Revolution Medicines, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-17 pm EDT			5-day change	1st Jan Change
157.77 ^USD	+0.76%		+9.42%	+98.08%

04:31am	Revolution Medicines Insider Sold Shares Worth $14,972,110, According to a Recent SEC Filing	MT
Jun. 08	Top Midday Gainers	MT

Published on 09/11/2025 at 02:20 am EDT - Modified on 09/11/2025 at 06:35 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by, and welcome to Revolution Medicines Conference Call. Today's program is being recorded. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

04:31am	Revolution Medicines Insider Sold Shares Worth $14,972,110, According to a Recent SEC Filing	MT
Jun. 08	Top Midday Gainers	MT
Jun. 08	Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand	MT
Jun. 08	Tango Therapeutics' pancreatic cancer drug combo shows promise in study	RE
Jun. 08	Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-Bell	MT
Jun. 03	'It's still working': More are living with cancer as era of targeted drugs takes hold	RE
Jun. 02	Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says	MT
Jun. 02	RBC Raises Price Target on Revolution Medicines to $182 From $165, Keeps Outperform, Speculative Risk	MT
Jun. 01	Revolution Medicines' Trial Data Shows Daraxonrasib is 'Winner' in Pancreatic Cancer Treatment, RBC Says	MT
Jun. 01	Wall Street Starts June on Edge
Jun. 01	Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating	MT
Jun. 01	Summit drops as concerns over older patients cloud cancer trial data	RE
Jun. 01	AI and 1984	RE
Jun. 01	MORNING BID AMERICAS-AI and 1984	RE
Jun. 01	Revolution Medicines Says Phase 3 Daraxonrasib Trial Shows Survival Benefit in Metastatic Pancreatic Cancer	MT